

Bernard J Gersh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/289808/bernard-j-gersh-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

362
papers

33,472
citations

75
h-index

180
g-index

425
ext. papers

40,920
ext. citations

8.5
avg, IF

6.97
L-index

#	Paper	IF	Citations
362	Risk of left atrial appendage thrombus and stroke in patients with atrial fibrillation and mitral regurgitation. <i>Heart</i> , 2022 , 108, 29-36	5.1	
361	Functional classification of left ventricular remodelling: prognostic relevance in myocardial infarction.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
360	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration.. <i>Circulation</i> , 2022 , 145, 392-409	16.7	4
359	Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008991	7.6	0
358	The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study.. <i>Contemporary Clinical Trials</i> , 2022 , 106732	2.3	
357	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.. <i>American Heart Journal</i> , 2022 , 251, 13-13	4.9	0
356	Artificial Intelligence-Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts.. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 871-880	6.4	0
355	Cardiac involvement in the long-term implications of COVID-19. <i>Nature Reviews Cardiology</i> , 2021 ,	14.8	18
354	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021 , 8,	3	1
353	Stem Cells in Cardiovascular Diseases: 30,000-Foot View. <i>Cells</i> , 2021 , 10,	7.9	2
352	Fibrinolysis vs. primary percutaneous coronary intervention for ST-segment elevation myocardial infarction cardiogenic shock. <i>ESC Heart Failure</i> , 2021 , 8, 2025-2035	3.7	1
351	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 553-561	4	0
350	Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. <i>ESC Heart Failure</i> , 2021 , 8, 2306-2309	3.7	2
349	To stent or not to stent? Treating angina after ISCHEMIA-the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2021 , 42, 1389-1393	9.5	0
348	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010300	6	7
347	Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. <i>American Journal of Cardiology</i> , 2021 , 145, 64-68	3	2
346	Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021 , 144, 52-59	3	5

345	To stent or not to stent? Treating angina after ISCHEMIA-introduction. <i>European Heart Journal</i> , 2021 , 42, 1387-1388	9.5	1
344	International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2466-2476	15.1	25
343	Temporal Trends, Management and Outcomes of Acute Myocardial Infarction with Concomitant Respiratory Infections. <i>American Journal of Cardiology</i> , 2021 , 150, 1-7	3	2
342	Patterns of oral anticoagulation use with cardioversion in clinical practice. <i>Heart</i> , 2021 , 107, 642-649	5.1	0
341	Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. <i>Nature Reviews Cardiology</i> , 2021 , 18, 155-168	14.8	21
340	Late Health Status of Patients Undergoing Myectomy for Obstructive Hypertrophic Cardiomyopathy. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1867-1875	2.7	7
339	Nonobstructive Hypertrophic Cardiomyopathy in a Patient With Mitral Prosthesis. <i>Annals of Thoracic Surgery</i> , 2021 , 111, e429-e432	2.7	1
338	Systolic-to-diastolic myocardial volume ratio as a novel imaging marker of cardiomyopathy. <i>International Journal of Cardiology</i> , 2021 , 322, 272-277	3.2	1
337	Utilization and procedural adverse outcomes associated with Watchman device implantation. <i>Europace</i> , 2021 , 23, 247-253	3.9	3
336	Comparative effectiveness of oral anticoagulants in everyday practice. <i>Heart</i> , 2021 ,	5.1	5
335	Ten-year trends, predictors and outcomes of mechanical circulatory support in percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock. <i>EuroIntervention</i> , 2021 , 16, e1254-e1261	3.1	33
334	Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. <i>Diabetology and Metabolic Syndrome</i> , 2021 , 13, 17	5.6	2
333	Myocardial contraction fraction by echocardiography and mortality in cardiac intensive care unit patients. <i>International Journal of Cardiology</i> , 2021 , 344, 230-239	3.2	2
332	Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. <i>American Heart Journal</i> , 2021 , 239, 73-79	4.9	5
331	Use of Artificial Intelligence Tools Across Different Clinical Settings: A Cautionary Tale. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e008153	5.8	1
330	Improving Communication of Incidental Imaging Findings: Transforming Uncertainty Into Opportunity. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2753-2756	6.4	
329	Gaps in Evidence for Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2021 , 143, 101-103	16.7	6
328	Postoperative Atrial Fibrillation After Noncardiac Surgery and Stroke-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 187-188	27.4	

327	Weekend Effect in the Management and Outcomes of Acute Myocardial Infarction in the United States, 2000-2016. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020 , 4, 362-372	3.1	13
326	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e007775	6.4	3
325	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 263-272	4.6	2
324	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008688	6.4	10
323	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2287-2295	15.4	5
322	Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. <i>Heart Rhythm</i> , 2020 , 17, 1057-1065	6.7	26
321	Impact of Diabetes Mellitus on Stroke and Survival in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020 , 131, 33-39	3	8
320	Is Cardioprotection Salvageable?. <i>Circulation</i> , 2020 , 141, 415-417	16.7	20
319	Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2020 , 3, e200107	10.4	11
318	Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 722-733	15.1	55
317	Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States. <i>Circulation: Heart Failure</i> , 2020 , 13, e006661	7.6	44
316	Left ventricular remodelling after ST-segment elevation myocardial infarction: sex differences and prognosis. <i>ESC Heart Failure</i> , 2020 , 7, 474-481	3.7	4
315	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2020 , 226, 85-93	4.9	4
314	Pulmonary artery catheter use in acute myocardial infarction-cardiogenic shock. <i>ESC Heart Failure</i> , 2020 , 7, 1234-1245	3.7	31
313	Burden of Arrhythmias in Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2020 , 125, 1774-1781	3	25
312	Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. <i>American Journal of Cardiology</i> , 2020 , 127, 16-24	3	1
311	Usefulness of Discharge Resting Heart Rate to Predict Adverse Cardiovascular Outcomes in Patients With Left Main Coronary Artery Disease Revascularized With Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting (from the EXCEL Trial). <i>American Journal of Cardiology</i> , 2020 , 125, 169-175	3	1
310	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. <i>American Heart Journal</i> , 2020 , 219, 21-30	4.9	6

309	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. <i>American Heart Journal</i> , 2020 , 223, 65-71	4.9	14
308	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. <i>American Heart Journal</i> , 2020 , 219, 128-136	4.9	8
307	Incidence and Prognostic Impact of Atrial Fibrillation After Discharge Following Revascularization for Significant Left Main Coronary Artery Narrowing. <i>American Journal of Cardiology</i> , 2020 , 125, 500-506 ³		1
306	Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort. <i>Circulation</i> , 2020 , 141, 454-463	16.7	38
305	Left Ventricular Post-Infarct Remodeling: Implications for Systolic Function Improvement and Outcomes in the Modern Era. <i>JACC: Heart Failure</i> , 2020 , 8, 131-140	7.9	34
304	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 301-309	6.4	15
303	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020 , 141, 10-20	16.7	11
302	Transcatheter Aortic Valve Replacement in Low-Risk, Young Patients: Natural Expansion or Cause for Concern?. <i>Circulation</i> , 2020 , 142, 1317-1319	16.7	4
301	Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young. <i>Circulation: Heart Failure</i> , 2020 , 13, e007154	7.6	31
300	Prognostic significance of patent foramen ovale in anticoagulated patients with atrial fibrillation. <i>Open Heart</i> , 2020 , 7, e001229	3	
299	In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020 , 4, 511-520	3.1	1
298	Professor Lionel H. Opie 6th May 1933-20th February 2020. <i>European Heart Journal</i> , 2020 , 41, 1620-1621 ^{9.5}		
297	Epidemiological Trends in the Timing of In-Hospital Death in Acute Myocardial Infarction-Cardiogenic Shock in the United States. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
296	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). <i>American Journal of Cardiology</i> , 2020 , 132, 66-71	3	0
295	Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. <i>JAMA Network Open</i> , 2020 , 3, e2025505	10.4	18
294	Influence of seasons on the management and outcomes acute myocardial infarction: An 18-year US study. <i>Clinical Cardiology</i> , 2020 , 43, 1175-1185	3.3	9
293	Management and outcomes of uncomplicated ST-segment elevation myocardial infarction patients transferred after fibrinolytic therapy. <i>International Journal of Cardiology</i> , 2020 , 321, 54-60	3.2	5
292	Relationship Between Anemia and Sudden Cardiac Death in Patients With Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2020 , 136, 107-114	3	1

291	Cardiopietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. <i>ESC Heart Failure</i> , 2020 , 7, 3345	3.7	12
290	Association of New-Onset Atrial Fibrillation After Noncardiac Surgery With Subsequent Stroke and Transient Ischemic Attack. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 871-878	27.4	9
289	Prognostic Implications of Significant Isolated Tricuspid Regurgitation in Patients With Atrial Fibrillation Without Left-Sided Heart Disease or Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2020 , 135, 84-90	3	4
288	Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. <i>The Lancet Digital Health</i> , 2020 , 2, e486-e488	14.4	35
287	Complications from percutaneous-left ventricular assist devices versus intra-aortic balloon pump in acute myocardial infarction-cardiogenic shock. <i>PLoS ONE</i> , 2020 , 15, e0238046	3.7	8
286	Sex and Gender Disparities in the Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Older Adults. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 1916-1927	6.4	23
285	Association of Autoimmune Vasculitis and Incident Atrial Fibrillation: A Population-Based Case-Control Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e015977	6	2
284	Modern Management of ST-Segment Elevation Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2020 , 45, 100393	17.1	12
283	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. <i>European Heart Journal</i> , 2020 , 41, 1764-1774	9.5	7
282	Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 82-92	4.3	6
281	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020 , 220, 145-154	4.9	1
280	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
279	Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock. <i>PLoS ONE</i> , 2019 , 14, e0222894	3.7	42
278	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. <i>American Heart Journal</i> , 2019 , 213, 81-90	4.9	4
277	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005358	5.8	25
276	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 27-34	5.1	4
275	Atrial fibrillation ablation in practice: assessing CABANA generalizability. <i>European Heart Journal</i> , 2019 , 40, 1257-1264	9.5	63
274	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019 , 42, 568-577	2.3	43

273	Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1781-1791	15.1	109
272	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 345-352	5.1	8
271	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2019 , 123, 1628-1636	3	5
270	Arrhythmia Endpoints in Interventional Cardiovascular Trials: A Missed Opportunity?. <i>Structural Heart</i> , 2019 , 3, 20-23	0.6	
269	An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. <i>Lancet, The</i> , 2019 , 394, 861-867	40	360
268	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (From the REVEAL AF Study). <i>American Journal of Cardiology</i> , 2019 , 124, 864-870	3	4
267	Association Between Stress Testing-Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2019 , 179, 1345-1351	11.5	8
266	Utilization of Palliative Care for Cardiogenic Shock Complicating Acute Myocardial Infarction: A 15-Year National Perspective on Trends, Disparities, Predictors, and Outcomes. <i>Journal of the American Heart Association</i> , 2019 , 8, e011954	6	63
265	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 83-99	15.1	84
264	Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock. <i>ESC Heart Failure</i> , 2019 , 6, 874-877	3.7	46
263	Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. <i>Annals of Intensive Care</i> , 2019 , 9, 96	8.9	49
262	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019 , 218, 100-109	4.9	4
261	Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014. <i>Circulation: Heart Failure</i> , 2019 , 12, e005929	7.6	54
260	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019 , 105, 235-242	5.1	11
259	Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?. <i>American Heart Journal</i> , 2019 , 209, 54-62	4.9	5
258	Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2019 , 123, 489-497	3	49
257	The hypertrophic cardiomyopathy paradox: better with age. <i>European Heart Journal</i> , 2019 , 40, 994-996	9.5	3
256	Stroke prevention in atrial fibrillation: Closing the gap. <i>American Heart Journal</i> , 2019 , 210, 29-38	4.9	6

255	Risk stratification for stroke in atrial fibrillation: a critique. <i>European Heart Journal</i> , 2019 , 40, 1294-1302	9.5	20
254	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. <i>Heart</i> , 2019 , 105, 370-377	5.1	17
253	B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. <i>Circulation</i> , 2018 , 138, 469-478	16.7	14
252	Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. <i>Circulation</i> , 2018 , 137, 2427-2429	16.7	3
251	Hypertrophic Cardiomyopathy: Clinical Update. <i>JACC: Heart Failure</i> , 2018 , 6, 364-375	7.9	96
250	Revascularization in stable coronary disease: evidence and uncertainties. <i>Nature Reviews Cardiology</i> , 2018 , 15, 408-419	14.8	13
249	High Prevalence of Occult Heart Failure With Preserved Ejection Fraction Among Patients With Atrial Fibrillation and Dyspnea. <i>Circulation</i> , 2018 , 137, 534-535	16.7	40
248	New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 739-748	15.1	65
247	Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 145-154	6.4	34
246	Coronary Artery Disease in Patients 80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2015-2040	15.1	81
245	Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent Transesophageal-Guided Electrical Cardioversion for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018 , 121, 1540-1547	3	7
244	Sex Differences in Long-Term Cause-Specific Mortality After Percutaneous Coronary Intervention: Temporal Trends and Mechanisms. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006062	6	16
243	Transcatheter aortic valve implantation in lower-risk patients: what is the perspective?. <i>European Heart Journal</i> , 2018 , 39, 658-666	9.5	42
242	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 435-439	5.1	7
241	Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
240	Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2018 , 131, 269-275.e2	2.4	60
239	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. <i>JAMA Cardiology</i> , 2018 , 3, 54-63	16.2	44
238	Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Prior Cerebrovascular Disease: Results From the EXCEL Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 2441-2450	5	4

237	Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Before Left Ventricular Assist Device Surgery. <i>Journal of the American Heart Association</i> , 2018 , 7, e010193	6	53
236	Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006930	6	65
235	Reappraisal of Ischemic Heart Disease. <i>Circulation</i> , 2018 , 138, 1463-1480	16.7	127
234	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1824-1833 ²³	16.7	127
233	Embolitic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2018 , 122, 1677-1683	3	6
232	Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2116-2126	27.4	69
231	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 753-770	4.3	40
230	Burden of Arrhythmia in Pregnancy. <i>Circulation</i> , 2017 , 135, 619-621	16.7	56
229	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence?. <i>Circulation</i> , 2017 , 135, 819-821	16.7	12
228	Incidence of Idiopathic Ventricular Arrhythmias: A Population-Based Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017 , 10,	6.4	27
227	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis. <i>Circulation</i> , 2017 , 135, 714-716	16.7	32
226	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2017 , 135, 1851-1867	16.7	302
225	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017 , 189, 40-47	4.9	40
224	Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. <i>European Journal of Heart Failure</i> , 2017 , 19, 457-465	12.3	12
223	Impact of Left Atrial Appendage Closure During Cardiac Surgery on the Occurrence of Early Postoperative Atrial Fibrillation, Stroke, and Mortality: A Propensity Score-Matched Analysis of 10 633 Patients. <i>Circulation</i> , 2017 , 135, 366-378	16.7	82
222	Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2779-2790	15.1	289
221	Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , 2017 , 19, 1520-1529	12.3	66
220	Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2017 , 5, 44-52	7.9	54

219	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017 , 130, 449-456	2.4	16
218	Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. <i>American Heart Journal</i> , 2017 , 185, 74-84	4.9	41
217	Women with hypertrophic cardiomyopathy have worse survival. <i>European Heart Journal</i> , 2017 , 38, 3434-3440	9.5	85
216	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017 , 48, 3266-3273	6.7	13
215	Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials. <i>Heart Rhythm</i> , 2017 , 14, 1839-1848	6.7	4
214	The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	37
213	Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. <i>JAMA Cardiology</i> , 2017 , 2, 1120-1127	16.2	135
212	Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1325-1335	15.1	65
211	Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study. <i>Clinical Cardiology</i> , 2017 , 40, 982-987	3.3	3
210	Comparison of the CHADS-VASc, CHADS, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017 , 120, 1549-1556	3	36
209	Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2621-2632	15.1	118
208	Response by Vaidya et al to Letter Regarding Article, "Burden of Arrhythmia in Pregnancy". <i>Circulation</i> , 2017 , 136, 244-245	16.7	
207	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	15
206	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. <i>American Heart Journal</i> , 2017 , 185, 59-66	4.9	11
205	Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 192-197	4.6	38
204	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 114-122	4.6	23
203	Cardiopietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017 , 38, 648-660	9.5	113
202	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUTE) trials. <i>American Heart Journal</i> , 2016 , 171, 49-7	4.9	24

201	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 661-3	27.4	26
200	Regression to the Mean in SYMPLICITY-HTN-3: Implications for Design and Reporting of Future Trials. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2016-2025	15.1	36
199	Revascularization in Patients With Severe Left Ventricular Dysfunction: Is the Assessment of Viability Still Viable?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2874-87	15.1	33
198	Are Zebras Simply Striped Horses?. <i>Circulation</i> , 2016 , 133, 434-41	16.7	
197	Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. <i>JACC: Clinical Electrophysiology</i> , 2016 , 2, 221-229	4.6	22
196	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016 , 129, 592-599.e1	2.4	40
195	Impact of Socioeconomic Status, Ethnicity, and Urbanization on Risk Factor Profiles of Cardiovascular Disease in Africa. <i>Circulation</i> , 2016 , 133, 1199-208	16.7	45
194	Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. <i>JACC: Clinical Electrophysiology</i> , 2016 , 2, 355-363	4.6	32
193	The rise, fall, and possible resurrection of renal denervation. <i>Nature Reviews Cardiology</i> , 2016 , 13, 238-44	14.8	28
192	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016 , 102, 508-17	5.1	51
191	Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016 , 9, e003283	6.4	36
190	The Natural History of Nonobstructive Hypertrophic Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 279-87	6.4	22
189	Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2016 , 17, 604-10	4.1	41
188	Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. <i>Heart Rhythm</i> , 2016 , 13, 1418-24	6.7	80
187	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	232
186	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016 , 202, 589-94	3.2	29
185	A Clinical Perspective on Sudden Cardiac Death. <i>Arrhythmia and Electrophysiology Review</i> , 2016 , 5, 177-182	18.2	31
184	Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, 962-970	2.7	13

183	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2597-2604	15.1	291
182	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-Analysis of Quality of Life, Morbidity, and Mortality. <i>JACC: Clinical Electrophysiology</i> , 2016 , 2, 170-180	4.6	25
181	Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2016 , 175, 28-35	4.9	20
180	Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network). <i>American Journal of Cardiology</i> , 2016 , 117, 1904-10	3	14
179	Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	15
178	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016 , 134, 1122-1127	16.7	2
177	Patient factors associated with quality of life in atrial fibrillation. <i>American Heart Journal</i> , 2016 , 182, 1354-13	4.3	32
176	Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. <i>European Journal of Heart Failure</i> , 2016 , 18, 160-8	12.3	58
175	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. <i>Clinical Cardiology</i> , 2016 , 39, 119-25	3.3	4
174	Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy. <i>Congenital Heart Disease</i> , 2015 , 10, E139-45	3.1	26
173	Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 605-16	13.2	40
172	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2691-8	15.1	66
171	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Circulation</i> , 2015 , 132, 624-32	16.7	159
170	Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2015 , 169, 647-654.e2	4.9	137
169	Heart rate is associated with progression of atrial fibrillation, independent of rhythm. <i>Heart</i> , 2015 , 101, 894-9	5.1	39
168	Prediction of Cardiac and Noncardiac Mortality After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002121	6	10
167	Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	38
166	Anticoagulation in Atrial Fibrillation - Current Concepts. <i>Arrhythmia and Electrophysiology Review</i> , 2015 , 4, 100-7	3.2	4

165	Atrial fibrillation pathophysiology and prognosis: insights from cardiovascular imaging. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8,	3.9	7
164	Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015 , 4,	6	20
163	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	46
162	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 653-6	9.5	41
161	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 27-38	15.1	54
160	Prognosis following acute coronary syndromes according to prior coronary artery bypass grafting: Meta-analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 518-27	4.3	4
159	Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. <i>Clinical Chemistry</i> , 2015 , 61, 368-78	5.5	29
158	Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Circulation</i> , 2015 , 131, 488-94	16.7	179
157	Early Repolarisation Syndrome - New Concepts. <i>Arrhythmia and Electrophysiology Review</i> , 2015 , 4, 169-73.	3.2	
156	Left atrial mechanics: echocardiographic assessment and clinical implications. <i>Journal of the American Society of Echocardiography</i> , 2014 , 27, 463-78	5.8	159
155	Cell therapy for cardiac repair--lessons from clinical trials. <i>Nature Reviews Cardiology</i> , 2014 , 11, 232-46	14.8	222
154	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014 , 167, 735-42.e2	4.9	80
153	Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , 2014 , 383, 1933-43	40	469
152	High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 52-61	15.1	114
151	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014 , 170, 413-8	3.2	54
150	Timing of intervention and outcome in non-ST-elevation acute coronary syndromes: there is risk on both sides of the curve. <i>International Journal of Cardiology</i> , 2014 , 177, 23-4	3.2	5
149	Reply: Translation of regenerative technologies into clinical paradigms. <i>Nature Reviews Cardiology</i> , 2014 , 11, 553-4	14.8	
148	Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014 , 35, 2032-9	9.5	25

147	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, 772-91	1.5	47
146	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, e153-93	1.5	170
145	Do current clinical trials meet society's needs?: a critical review of recent evidence. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1615-28	15.1	44
144	The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. <i>European Heart Journal</i> , 2014 , 35, 1526-32	9.5	49
143	Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 75, 12-24	5.8	63
142	Rationale and design of REVEAL AF: a prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. <i>American Heart Journal</i> , 2014 , 167, 22-7	4.9	29
141	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. <i>American Heart Journal</i> , 2014 , 168, 160-7	4.9	53
140	Tratamiento de la miocardiopatía hipertrofica sintomática: ¿pastillas, alcohol o bisturí. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 341-344	1.5	4
139	Fabry disease with resting outflow obstruction masquerading as hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2014 , 63, e43	15.1	10
138	Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. <i>Journal of the American Heart Association</i> , 2014 , 3, e001002	6	145
137	Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 9-16	3	29
136	Inherited Arrhythmias - Where do we Stand?. <i>Arrhythmia and Electrophysiology Review</i> , 2014 , 3, 80-4	3.2	
135	Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 81, E58-67	2.7	47
134	Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?. <i>Lancet, The</i> , 2013 , 382, 624-32	4.0	48
133	Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. <i>American Journal of Medicine</i> , 2013 , 126, 625-32.e1	2.4	31
132	Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. <i>American Heart Journal</i> , 2013 , 165, 123-32	4.9	24
131	N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2274-84	15.1	149
130	Which therapy for which condition? 2013 , 463-541		

129	Modern management of acute myocardial infarction. <i>Current Problems in Cardiology</i> , 2012 , 37, 237-310	17.1	12
128	Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 597-604 ⁶		62
127	Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. <i>Circulation</i> , 2012 , 125, 2613-20	16.7	99
126	Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. <i>Circulation</i> , 2012 , 126, 2115-24	16.7	46
125	Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Circulation</i> , 2012 , 126, 2374-80	16.7	181
124	Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. <i>Journal of the American College of</i>	15.1	192
123	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic	15.1	792
122	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1109-112	15.1	194
121	Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. <i>American Heart Journal</i> , 2011 , 162, 606-612.e1	4.9	120
120	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
119	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 2193-204	40	358
118	Utility of left bundle branch block as a diagnostic criterion for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2011 , 107, 1111-6	3	85
117	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2011 , 124, 2761-96	16.7	587
116	Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. <i>European Heart Journal</i> , 2010 , 31, 642-8	9.5	302
115	New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy. <i>Circulation</i> , 2009 , 120, 1024-6	16.7	3
114	Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. <i>Circulation</i> , 2009 , 120, 2105-12	16.7	160
113	Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. <i>European Heart Journal</i> , 2009 , 30, 1038-45	9.5	365
112	Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2009 , 360, 1946-59	59.2	577

111	Cardiac Cell Repair Therapy: A Clinical Perspective. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 876-892	6.4	116
110	Cardiac cell repair therapy: a clinical perspective. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 876-92	6.4	48
109	Which Therapy for Which Condition? 2009 , 388-458		
108	Left atrial reservoir function as a potent marker for first atrial fibrillation or flutter in persons > or = 65 years of age. <i>American Journal of Cardiology</i> , 2008 , 101, 1626-9	3	159
107	Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. <i>American Heart Journal</i> , 2008 , 155, 829-40	4.9	14
106	From randomized trials to registry studies: translating data into clinical information. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 613-20		46
105	Bivalirudin during primary PCI in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2008 , 358, 2218-30	59.2	1457
104	Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Circulation</i> , 2008 , 118, 131-9	16.7	186
103	Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 350-7	15.1	162
102	Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 986-92	15.1	322
101	Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. <i>Circulation</i> , 2007 , 116, 729-36	16.7	260
100	Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls. <i>European Heart Journal</i> , 2007 , 28, 1545-53	9.5	20
99	Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>European Heart Journal</i> , 2007 , 28, 1709-16	9.5	311
98	Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, 503-12		93
97	Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. <i>Circulation</i> , 2007 , 115, 3050-6	16.7	277
96	Relation of arterial stiffness to left ventricular diastolic function and cardiovascular risk prediction in patients > or =65 years of age. <i>American Journal of Cardiology</i> , 2006 , 98, 1387-92	3	111
95	Selection of the optimal reperfusion strategy for STEMI: does time matter?. <i>European Heart Journal</i> , 2006 , 27, 761-3	9.5	37
94	Is facilitated percutaneous coronary intervention superior to primary percutaneous coronary intervention?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 356-7		

93	Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2006 , 19, 788-95	5.8	53
92	Controversies in ventricular remodelling. <i>Lancet, The</i> , 2006 , 367, 356-67	40	645
91	Facilitated angioplasty: paradise lost. <i>Lancet, The</i> , 2006 , 367, 543-6	40	32
90	Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. <i>Circulation</i> , 2006 , 114, 119-25	16.7	1817
89	Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter?. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1018-23	15.1	563
88	A total of 1,007 percutaneous coronary interventions without onsite cardiac surgery: acute and long-term outcomes. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1713-21	15.1	50
87	Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 779-86	15.1	140
86	Cardiac cell-repair therapy: clinical issues. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3 Suppl 1, S105-9		13
85	Aborted myocardial infarction: a new target for reperfusion therapy. <i>European Heart Journal</i> , 2006 , 27, 901-4	9.5	48
84	Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. <i>Stroke</i> , 2005 , 36, 2362-6	6.7	82
83	Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1397-405	15.1	367
82	Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 470-6	15.1	514
81	Revascularization in severe left ventricular dysfunction: the role of viability testing. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 567-74	15.1	99
80	Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 979-86	27.4	290
79	Epidemiological profile of atrial fibrillation: a contemporary perspective. <i>Progress in Cardiovascular Diseases</i> , 2005 , 48, 1-8	8.5	75
78	Cell therapy for cardiovascular disease: what cells, what diseases and for whom?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 37-43		18
77	Methods of coronary revascularization--things may not be as they seem. <i>New England Journal of Medicine</i> , 2005 , 352, 2235-7	59.2	74
76	Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. <i>European Heart Journal</i> , 2005 , 26, 667-74	9.5	145

75	The PEACE trial: ACE inhibitors and coronary artery disease. <i>Reviews in Cardiovascular Medicine</i> , 2005 , 6, 54-9	3.9	
74	Risks for atrial fibrillation and congestive heart failure in patients ≥ 65 years of age with abnormal left ventricular diastolic relaxation. <i>American Journal of Cardiology</i> , 2004 , 93, 54-8	3	131
73	The case for surgery in obstructive hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 2044-53	15.1	149
72	Do implantable cardioverter defibrillators lower mortality risk in patients with cardiomyopathy?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2004 , 1, 16-7		1
71	The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. <i>Transactions of the American Clinical and Climatological Association</i> , 2004 , 115, 149-59; discussion 159-60	0.9	24
70	The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 93-100	15.1	190
69	Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1199-205	15.1	302
68	Left atrial volume as a morphophysiological expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. <i>American Journal of Cardiology</i> , 2002 , 90, 1284-9	3	870
67	Defining gene transfer before expecting gene therapy: putting the horse before the cart. <i>Circulation</i> , 2002 , 106, 631-6	16.7	39
66	Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1636-44	15.1	498
65	Unrecognized myocardial infarction. <i>Annals of Internal Medicine</i> , 2001 , 135, 801-11	8	118
64	Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 467-75	6.4	454
63	Time to presentation with acute myocardial infarction in the elderly: associations with race, sex, and socioeconomic characteristics. <i>Circulation</i> , 2000 , 102, 1651-6	16.7	191
62	Prognostic value of treadmill exercise testing: a population-based study in Olmsted County, Minnesota. <i>Circulation</i> , 1998 , 98, 2836-41	16.7	128
61	Long-term outcome of women compared with men after successful coronary angioplasty. <i>Circulation</i> , 1995 , 91, 2876-81	16.7	60
60	Idiopathic ventricular fibrillation in out-of-hospital cardiac arrest survivors. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 1405-12	1.6	21
59	Mitral valve operation in postinfarction rupture of a papillary muscle: immediate results and long-term follow-up of 22 patients. <i>Mayo Clinic Proceedings</i> , 1992 , 67, 1023-30	6.4	103
58	Mechanical and electrical complications of acute myocardial infarction. <i>Mayo Clinic Proceedings</i> , 1990 , 65, 709-30	6.4	61

57	Programmed ventricular stimulation during variant angina: report of a case. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1989 , 12, 1878-83	1.6	
56	The natural history of lone atrial fibrillation. A population-based study over three decades. <i>New England Journal of Medicine</i> , 1987 , 317, 669-74	59.2	781
55	Hemodynamic and symptomatic consequences of ventricular pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1982 , 5, 903-10	1.6	43
54	Initial and early follow-up assessment of the clinical efficacy of the multiparameter-programmable pulse generator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1981 , 4, 417-31	1.6	8
53	The value of redundancy in chronic bipolar pacemaker electrode systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1980 , 3, 436-9	1.6	2
52	Restenosis: Etiologies and Prevention371-394		1
51	Blood Pressure and Cardiovascular Disease146-160		1
50	The Fetal Origins of Coronary Heart Disease279-286		1
49	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction397-425		2
48	Management of Overt Heart Failure659-680		1
47	Pericardial Disease: An Evidence-Based Approach to Diagnosis and Treatment735-748		2
46	What is Evidence-Based Cardiology?3-13		
45	Tobacco: Global Burden and Community Solutions103-113		
44	Glucose Abnormalities and Cardiovascular Disease:DysglycemiaAs an Emerging Cardiovascular Risk Factor161-169		
43	Physical Activity and Exercise in Cardiovascular Disease Prevention and Rehabilitation170-180		
42	Psychosocial Factors in the Primary and Secondary Prevention of Coronary Heart Disease: An Updated Systematic Review of Prospective Cohort Studies181-218		1
41	Emerging Approaches in Cardiovascular Prevention219-230		
40	A Critical Appraisal of the Cardiovascular History and Physical Examination14-23		

- 39 Ethnicity and Cardiovascular Disease 259-278
- 38 Molecular Genetics of Cardiovascular Disorders 287-299
- 37 Adjunctive Medical Therapy in Percutaneous Coronary Intervention 360-370
- 36 Fibrinolytic Therapy 426-443
- 35 Mechanical Reperfusion Strategies in Patients Presenting with Acute Myocardial Infarction 444-455
- 34 Adjunctive Antithrombotic Therapy for ST-Elevation Acute Myocardial Infarction 456-476
- 33 Pain Relief, General Management, and Other Adjunctive Treatments 477-487
- 32 Complications After Myocardial Infarction 488-506
- 31 Atrial Fibrillation: Antiarrhythmic Therapy 519-547
- 30 Atrial Fibrillation: Non-Pharmacologic Therapies 556-566
- 29 Prevention and Treatment of Life-Threatening Ventricular Arrhythmia and Sudden Death 577-586
- 28 Impact of Pacemakers: When and What Kind? 587-618
- 27 Prevention of Congestive Heart Failure and Treatment of Asymptomatic Left Ventricular Dysfunction 643-658
- 26 Acute Myocarditis and Dilated Cardiomyopathy 681-702
- 25 Other Cardiomyopathies 718-732
- 24 Finding Current Best Evidence to Practice Evidence-Based Cardiology 40-45
- 23 Rheumatic Heart Disease: Prevention and Acute Treatment 751-757
- 22 Indications for Surgery in Aortic Valve Disease 767-781

- 21 Balloon Valvuloplasty: Aortic Valve 782-795
- 20 Valve Repair and Choice of Valves 809-816
- 19 Diagnosis and Management of Infective Endocarditis 817-831
- 18 Antithrombotic Therapy after Heart Valve Replacement 832-836
- 17 Heart Disease and Pregnancy 853-863
- 16 Venous Thromboembolic Disease 864-876
- 15 Clinical Applications of External Evidence 889-891
- 14 Introduction to Decision Analysis 56-70
- 13 Valvular Heart Disease: Timing of Surgery 934-937
- 12 Assessing and Changing Cardiovascular Clinical Practices 71-88
- 11 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 1-2
- 10 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 837-838
- 9 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 887-888
- 8 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 89-90
- 7 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 327-328
- 6 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 395-396
- 5 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 517-518
- 4 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 575-576

- 3 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology641-642
- 2 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology733-734
- 1 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology749-750